J&J's Darzalex combination gains expanded label for multiple myeloma in Europe

The European label for J&J's Darzalex has been expanded to include newly diagnosed multiple myeloma patients eligible for stem cell transplant. Supported by Phase III trial data, the antibody is projected to generate significant revenue growth by 2030.